In summary, our data revealed that WYC-209 showed an anti-tumor effect on GC both in vitro and in vivo by down-regulating the expression of WNT4 via RARα, making it a prospective strategy in antitumor therapy. The gene discussed is RARA; the disease is neoplasm.